Axsome Therapeutics Inc (NASDAQ:AXSM) CFO Nick Pizzie bought 31,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 19th. The stock was purchased at an average cost of $3.10 per share, with a total value of $96,100.00. Following the purchase, the chief financial officer now directly owns 400 shares in the company, valued at approximately $1,240. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
NASDAQ AXSM opened at $3.40 on Friday. Axsome Therapeutics Inc has a 12 month low of $2.05 and a 12 month high of $6.45. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.95 and a quick ratio of 2.95. The stock has a market cap of $87.33 million, a PE ratio of -2.74 and a beta of -0.31.
Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Tuesday, May 8th. The company reported ($0.19) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.09. analysts expect that Axsome Therapeutics Inc will post -1.08 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. A.R.T. Advisors LLC acquired a new position in shares of Axsome Therapeutics during the 1st quarter valued at about $145,000. Sabby Management LLC acquired a new position in shares of Axsome Therapeutics during the 1st quarter valued at about $199,000. Goldman Sachs Group Inc. acquired a new position in shares of Axsome Therapeutics during the 4th quarter valued at about $238,000. Renaissance Technologies LLC acquired a new position in shares of Axsome Therapeutics during the 4th quarter valued at about $271,000. Finally, Sio Capital Management LLC acquired a new position in shares of Axsome Therapeutics during the 1st quarter valued at about $474,000. 16.49% of the stock is owned by institutional investors.
Several research analysts recently weighed in on AXSM shares. BTIG Research reissued a “buy” rating and issued a $16.00 target price on shares of Axsome Therapeutics in a research note on Sunday, April 29th. Zacks Investment Research downgraded shares of Axsome Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 31st. ValuEngine raised shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Finally, HC Wainwright started coverage on shares of Axsome Therapeutics in a research note on Thursday, June 7th. They issued a “buy” rating and a $10.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $15.30.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation.
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.